Viking Therapeutics Stock Buy Hold or Sell Recommendation

VKTX Stock  USD 30.89  1.16  3.90%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Viking Therapeutics is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Viking Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Viking Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Viking Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.
In addition, we conduct extensive research on individual companies such as Viking and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Execute Viking Therapeutics Buy or Sell Advice

The Viking recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Viking Therapeutics. Macroaxis does not own or have any residual interests in Viking Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Viking Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Viking TherapeuticsBuy Viking Therapeutics
Cautious Hold

Market Performance

Very WeakDetails

Volatility

Very steadyDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Follows the market closelyDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Viking Therapeutics has a Mean Deviation of 3.65, Standard Deviation of 5.16 and Variance of 26.59
Our recommendation module can be used to complement Viking Therapeutics trade recommendation provided by average analyst sentiment. It analyzes the firm's potential to grow using fundamental, technical, data market data available at the time. To make sure Viking Therapeutics is not overpriced, please validate all Viking Therapeutics fundamentals, including its current ratio, target price, and the relationship between the cash per share and short ratio . Given that Viking Therapeutics has a price to earning of (3.17) X, we advise you to double-check Viking Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Viking Therapeutics Trading Alerts and Improvement Suggestions

Viking Therapeutics generated a negative expected return over the last 90 days
Viking Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (109.96 M) with profit before overhead, payroll, taxes, and interest of 0.
Viking Therapeutics currently holds about 155.02 M in cash with (87.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02.
Viking Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 74.0% of the company outstanding shares are owned by institutional investors
Latest headline from zacks.com: Viking Therapeutics, Inc. Ascends While Market Falls Some Facts to Note

Viking Therapeutics Returns Distribution Density

The distribution of Viking Therapeutics' historical returns is an attempt to chart the uncertainty of Viking Therapeutics' future price movements. The chart of the probability distribution of Viking Therapeutics daily returns describes the distribution of returns around its average expected value. We use Viking Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Viking Therapeutics returns is essential to provide solid investment advice for Viking Therapeutics.
Mean Return
-0.62
Value At Risk
-10.98
Potential Upside
8.39
Standard Deviation
5.16
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Viking Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Viking Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument, such as Viking Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Viking Therapeutics back and forth among themselves.
Shares
Norges Bank2024-12-31
1.3 M
Pictet Asset Manangement Sa2024-12-31
1.2 M
Alliancebernstein L.p.2024-12-31
1.1 M
Susquehanna International Group, Llp2024-12-31
M
International Assets Investment Management, Llc2024-09-30
M
Perceptive Advisors Llc2024-12-31
995.9 K
Amvescap Plc.2024-12-31
872.8 K
Balyasny Asset Management Llc2024-12-31
860.4 K
Charles Schwab Investment Management Inc2024-12-31
728.7 K
Fmr Inc2024-12-31
16.7 M
Vanguard Group Inc2024-12-31
10.2 M
Note, although Viking Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Viking Therapeutics Cash Flow Accounts

202020212022202320242025 (projected)
Free Cash Flow(21.8M)(47.6M)(48.4M)(73.4M)(87.8M)(83.4M)
Other Non Cash Items138K29K1.3M(8.1M)272K423.6K
Net Income(39.5M)(55.0M)(68.9M)(85.9M)(110.0M)(104.5M)
Change In Cash20.7M(2.7M)10.3M18.9M(28.8M)(27.4M)
End Period Cash Flow29.1M26.4M36.6M55.5M26.7M20.3M
Investments41.6M38.0M54.8M(207.6M)(553.4M)(525.7M)
Depreciation277K296K291K292K(17.2M)(16.3M)
Change To Netincome3.7M5.8M6.1M8.7M10.0M10.5M

Viking Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Viking Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Viking Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Viking stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.55
β
Beta against Dow Jones0.68
σ
Overall volatility
5.31
Ir
Information ratio -0.1

Viking Therapeutics Volatility Alert

Viking Therapeutics exhibits very low volatility with skewness of -0.66 and kurtosis of 2.24. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Viking Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Viking Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Viking Therapeutics Implied Volatility

Viking Therapeutics' implied volatility exposes the market's sentiment of Viking Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Viking Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Viking Therapeutics stock will not fluctuate a lot when Viking Therapeutics' options are near their expiration.

Viking Therapeutics Fundamentals Vs Peers

Comparing Viking Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Viking Therapeutics' direct or indirect competition across all of the common fundamentals between Viking Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Viking Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Viking Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Viking Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Viking Therapeutics to competition
FundamentalsViking TherapeuticsPeer Average
Return On Equity-0.18-0.31
Return On Asset-0.15-0.14
Current Valuation2.56 B16.62 B
Shares Outstanding112.25 M571.82 M
Shares Owned By Insiders2.00 %10.09 %
Shares Owned By Institutions74.22 %39.21 %
Number Of Shares Shorted25.11 M4.71 M
Price To Earning(3.17) X28.72 X
Price To Book3.94 X9.51 X
EBITDA(150.92 M)3.9 B
Net Income(109.96 M)570.98 M
Cash And Equivalents155.02 M2.7 B
Cash Per Share2.02 X5.01 X
Total Debt1.12 M5.32 B
Debt To Equity0.01 %48.70 %
Current Ratio11.74 X2.16 X
Book Value Per Share7.89 X1.93 K
Cash Flow From Operations(87.79 M)971.22 M
Short Ratio4.71 X4.00 X
Earnings Per Share(1.01) X3.12 X
Price To Earnings To Growth(0.03) X4.89 X
Target Price99.29
Number Of Employees3618.84 K
Beta0.9-0.15
Market Capitalization3.47 B19.03 B
Total Asset908.32 M29.47 B
Retained Earnings(487.91 M)9.33 B
Working Capital879.8 M1.48 B
Current Asset15.2 M9.34 B
Current Liabilities1.98 M7.9 B
Net Asset908.32 M
Note: Disposition of 35000 shares by Brian Lian of Viking Therapeutics at 23.95 subject to Rule 16b-3 [view details]

Viking Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Viking . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Viking Therapeutics Buy or Sell Advice

When is the right time to buy or sell Viking Therapeutics? Buying financial instruments such as Viking Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Viking Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Municipals ETFs Thematic Idea Now

Municipals ETFs
Municipals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Municipals ETFs theme has 116 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Municipals ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.